School of Medicine Faculty Publications

School of Medicine

8-7-2020

BK Virus Nephropathy: Prevalence, Impact and Management
Strategies
Rajeev Sharma
University of Nevada, Las Vegas

Mareena Zachariah
Wayne State University

Follow this and additional works at: https://digitalscholarship.unlv.edu/som_fac_articles
Part of the Nephrology Commons

Repository Citation
Sharma, R., Zachariah, M. (2020). BK Virus Nephropathy: Prevalence, Impact and Management Strategies.
International Journal of Nephrology and Renovascular Disease, 13 1-6.
http://dx.doi.org/10.2147/IJNRD.S236556

This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV
with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the
copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from
the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/
or on the work itself.
This Article has been accepted for inclusion in School of Medicine Faculty Publications by an authorized
administrator of Digital Scholarship@UNLV. For more information, please contact digitalscholarship@unlv.edu.

International Journal of Nephrology and Renovascular Disease

Dovepress

open access to scientific and medical research

International Journal of Nephrology and Renovascular Disease downloaded from https://www.dovepress.com/ by 131.216.14.120 on 09-Sep-2020
For personal use only.

Open Access Full Text Article

BK Virus Nephropathy: Prevalence, Impact and
Management Strategies
This article was published in the following Dove Press journal:
International Journal of Nephrology and Renovascular Disease

Rajeev Sharma 1,2
Mareena Zachariah 3
1

School of Medicine, University of
Nevada Las Vegas, Las Vegas, NV, USA;
2
Jacobs School of Medicine and
Biomedical Sciences, University at
Buffalo, Buffalo, NY, USA; 3Department
of Nephrology, Wayne State University,
Detroit, MI, USA

Abstract: BK virus reactivation as a result of therapeutic immunosuppression following
renal transplant can result in BK polyomavirus nephropathy and renal allograft loss. This is
a complex and challenging clinical problem with a range of management options and
practices reported in literature. The current standard for early diagnosis and treatment is
surveillance by measuring viral DNA in blood using qPCR. Immunosuppression reduction is
the cornerstone of effective management but is associated with a risk of acute rejection
following treatment.
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BK polyoma virus (BKV) is a non-enveloped DNA virus first discovered in the
urine of a kidney transplant recipient in 1971.1 Its genome has an early region
which codes for the large and small T antigens, a late region which codes for the
capsid proteins VP1-3, and agnoprotein, and a non-coding control region (NCCR).
BKV strains have six genotypes based on polymorphisms in VP1 and NCCR.2
BKV is widely prevalent in general population with over 80% individuals
having antibodies against BK virus.3,4 The most common mode of transmission is
through respiratory secretions, resulting in a mild self-limited respiratory infection.5
Viral spread to other organs is believed to be via bloodstream and in immunocom
petent individuals, it remains clinically silent in renal tubular epithelium.
“Presumptive” BK Polyoma virus nephropathy (PVN) is defined as persistently
high BK viral load in plasma >10,000 copies/mL for four weeks. Renal allograft
biopsy remains the gold standard for diagnosing “definite” PVN.6–12 Since the
allograft involvement is focal, and the possibility of sampling error is high, two
cores containing medulla are required for an adequate biopsy sample.8,9 Intragraft
polyomavirus gene expression on renal biopsy has recently been reported as
a useful adjunct to the diagnosis of PVN with the potential to differentiate from
T-cell-mediated rejection.13 Biopsy proven “definite” PVN has an incidence of
5–6%, with a higher incidence in ABO-incompatible donors and following desen
sitization in highly sensitized recipients.14–16
The Banff Working Group on Polyomavirus Nephropathy recently published
a morphologic classification of definite PVN into three groups, Class I, II, and III,
based on polyomavirus load and Banff ci score (interstitial fibrosis) for ease of
diagnostic communication and comparative data analysis.17 However, this was
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a retrospective observational analysis which has not been
validated in a mixed population.

Impact
BK-virus-related disease is commonly seen in kidney trans
plant and hematopoietic stem cell transplant recipients. The
cause for reactivation is therapeutic immunosuppression (IS)
following transplant.18 BK viruria can be seen in 60% of
kidney transplant recipients, while BK viremia is seen in up
to 13% kidney transplant recipients, and nephropathy in
10%.19–21 The actual reported incidence varies; however,
with the choice of induction IS, maintenance IS, and screen
ing modality used, hence the wide variations in literature. In
US, 5.7%– 7.5% of renal allografts are lost to PVN.22
PVN is therefore a serious clinical problem in kidney
transplantation. PVN is difficult to treat since there is no
BKV-specific anti-viral therapy. Any anti-virals currently in
use work poorly and suffer from substantial host toxicity.
PVN is treated by stimulating host immune response by IS
reduction; however, there is a risk of acute rejection follow
ing virus clearance,23 further complicating treatment options
since rejection treatment requires escalation of IS which
often results in BKV recurrence.
The current standard for management is monitoring for
viral DNA using qPCR. Other investigational surveillance
tools include monitoring BKV-specific CMIR,24 and
donor-derived cell-free DNA (dd-cfDNA). dd-cfDNA is

Dovepress

a non-specific marker of injury. Since BKV causes inter
stitial inflammation and tubulitis, elevated levels of ddcfDNA have been reported in a study of allograft rejection
in kidney transplant in the setting of PVN.25 Since BKV is
also known to be associated with development of de novo
donor-specific antibodies (DSA),26 elevated dd-cfDNA
levels in this infection could actually represent alloanti
body-mediated microcirculation injury. Persistent viremia
(lasting >140 days) was found to be strongly associated
with development of Class II DSAs. The association of
Class II DSA with antibody-mediated rejection (ABMR)
and graft loss is well known.27
Most studies have found that humoral immune response
does not play a significant role in preventing development
of PVN.28 Despite the presence of a high level of antibo
dies, patients with PVN can have high levels of viral load
and low CD8+ T cells.29 BKV-specific cell-mediated
immune response (CMIR) was demonstrated in normal
individuals to be the mechanism responsible for prevention
of BKV reactivation in immunocompetent individuals.30
Low levels of BKV-specific interferon-gamma (IFNγ) pro
ducing T cells correlate with progression to PVN, while
reconstitution of these cells correlates with resolution of
nephropathy.31–34 Immune monitoring could help in identi
fying patients at risk of PVN;34–38 however, this knowledge
is still evolving and has not been used in guiding treatment
recommendations.

Figure 1 Monitoring and treatment protocol for BK viremia at our center.
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Management Strategies
Risk Factors

Immunosuppression Reduction and
Antiviral Therapy

The most common factor associated with risk of developing
PVN is the intensity of immunosuppression. Donor factors
associated with a higher risk include transplanting kidney
from BKV seropositive donor to seronegative donor,39,40
number of HLA mismatches, ABO-incompatibility, and
ischemia reperfusion injury.6,14,41,42 Recipient factors include
old age, male sex, desensitization, and prior kidney transplant
with PVN.16,43

For BKV viral load <10,000 copies/mL, IS dose reduction
should be considered. For viral loads >10,000 copies/mL,
a common initial approach involves calcineurin inhibitor
dose reduction by 25–50%. Switching to Cyclosporine
A (CsA) has been shown to have some benefit as well.45
Switching from Tacrolimus to CsA is a common approach
used in our center in patients with persistent viremia;
However, a higher incidence of biopsy-proven acute rejection
is seen with this approach.46 Failure of reduction in viral load
should prompt reduction of mycophenolate mofetil (MMF) by
50%, or discontinuation of MMF or switching to an mTOR
inhibitor.47,48 Switching from MMF to Leflunomide is another
option associated with favorable outcomes.49–52 We routinely
switch from MMF to Leflunomide in our center; however, the
practices vary by center and physician experience. In refrac
tory cases, most common therapeutic option is Cidofovir, use
of which is limited by its nephrotoxicity.53–55 Brincidofovir is
a prodrug of cidofovir and has also been used with limited
success.56,57 IVIG preparations have high titers of neutralizing
antibodies to BK virus and can help expedite virus clearance
and have been used as a useful adjunctive therapy.58–61
Fluoroquinolones have been tried but failed to show

Surveillance
The mainstay of treatment of PVN is immunosuppression
reduction. A wide variation in treatment practices is
observed based on individual clinician experience. Most
centers monitor BKV post-transplant at 3, 6, 9, and 12
months.44 However, with more intense induction regimen
or in those with risk factors, it is prudent to perform
routine surveillance at monthly intervals in the first 12
months following transplant. This is standard in our center.
In addition to following viral loads with qPCR, we also
follow ImmuKnow Immune Cell Function Assay (Cylex
Inc., Columbia, MD, USA) as an indirect measure of
CMIR. Our approach is outlined in Figure 1.

Table 1 Anti-Virals for PVN
Anti-Virals
Name
Leflunomide

49–52

Class/Mechanism

Dose

Comments

Anti-Inflammatory; Anti-Viral;
Immunosuppressive

PO: Loading- 100 mg daily for 3–5
days; maintenance- 20-60 mg qD;

Can be used following
discontinuation of MMF.

Trough Level −50-100 μg/mL
Cidofovir53–55

Nucleoside analog

IV: 0.25–1.0 mg/Kg at 1–3 weeks

Used in refractory cases;
Nephrotoxicity is the most
serious adverse effect.

Brincidofovir56,57

Investigational Prodrug of Cidofovir; Anti-viral

PO: 2 mg/Kg twice weekly

Reasonably well tolerated;

activity
Intravenous

Immunoglobulin preparation with high titers of

immunoglobulin
(IVIG)58–61

neutralizing antibodies to BK virus

Levofloxacin62–64

Fluoroquinolones; Antiviral, inhibit helicase
activity of large T antigen

Investigational.
IV: 0.25–2.0 g/Kg

Can be used as an adjunct to
other measures in refractory
cases.

PO: 500 mg qD (renally adjusted)

Levofloxacin failed to show
benefit in randomized controlled
trials.

Everolimus47,48

Inhibits mammalian target of rapamycin (mTOR)

PO 0.75 mg twice daily adjusted to

Can be used following

kinase activity, inhibiting T and B lymphocyte

trough levels of 3–8 ng/mL.

discontinuation of MMF. Limited

activation and proliferation.
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therapeutic benefit.62–64 There is no strong evidence support
ing antiviral treatment for PVN;46 however, for patients with
persistent BK viremia despite adequate immunosuppression
reduction, therapeutic options are outlined in Table 1.

Conclusion
Due to lack of strong evidence, no strong treatment recom
mendations can be made; however, it is prudent to start
with immunosuppression reduction and add anti-virals for
persistent viremia not responding to immunosuppression
reduction based on physician experience. Regular monitor
ing of qPCR remains the cornerstone of early diagnosis
and treatment. Novel monitoring strategies being investi
gated include immune monitoring and ddcf DNA.

Abbreviations
BKV, BK virus; NCCR, non-coding control region; PVN,
BK polyoma virus nephropathy; qPCR, quantitative poly
merase chain reaction; ddcfDNA, donor-derived cell-free
DNA; DSA, donor-specific antibodies; ABMR, antibodymediated rejection; CMIR, cell-mediated immune
response; JCV, JC virus; IFNγ, interferon-gamma; MMF,
mycophenolate mofetil; CsA, cyclosporine A; ATP, adeno
sine triphosphate; ELISPOT, enzyme-linked immunoSpot;
IS, Immunosuppression; PML, progressive multifocal
leukoencephalopathy.
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